March 25, 2020
Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559
Contact Media Relations
Thursday, November 19, 2020
Promising Results Seen in Pfizer/BioNTech COVID-19 Vaccine After Phase 1 Trial by University of Maryland School of Medicine
Just six months after beginning a clinical development program that first enrolled here at the University of Maryland School of Medicine (UMSOM), Pfizer and BioNTech report interim results showing an mRNA COVID-19 vaccine had no serious safety concerns and has been found to be 95 percent effective in protecting individuals from COVID-19.
Tuesday, June 02, 2020
UM School of Medicine’s Institute of Human Virology Awarded Grants to Strengthen COVID-19 Response in Sub-Saharan Africa
The Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine’s Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention (CDC) to support coronavirus disease 2019 (COVID-19) response activities in Botswana, Nigeria, Malawi, and Mozambique.
Monday, June 01, 2020
In the U.S., our children rarely fall ill to grave infections because they are protected by vaccines. Serious illnesses like measles, mumps, congenital rubella syndrome, chickenpox, diphtheria, tetanus, whooping cough, rotavirus diarrhea, hepatitis (A and B), polio and bacterial meningitis are all preventable through routine childhood vaccinations.
Tuesday, May 05, 2020
In a significant development in the global effort to discover a safe and effective vaccine for COVID-19, researchers at the University of Maryland School of Medicine (UMSOM) became the first in the U.S. to begin testing experimental COVID-19 vaccine candidates developed by Pfizer and BioNTech. The research, funded by Pfizer Inc., will study the safety, efficacy, and dosing of an experimental mRNA -based vaccine.
Thursday, April 23, 2020
Researchers at the University of Maryland School of Medicine (UMSOM) are testing the effectiveness of the investigational antiviral drug remdesivir in hospitalized adult patients with SARS-CoV-2 (COVID-19). The randomized controlled clinical trial is evaluating the safety and effectiveness of the drug, and it is part of a national study funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
Friday, April 10, 2020
University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a large-scale COVID-19 Testing Initiative that will significantly expand testing capability over the coming weeks, enabled by new funding of $2.5 million from the State of Maryland.
Wednesday, April 01, 2020
I am sure you are aware of Governor Hogan’s Executive Order that requires all residents of Maryland to stay at home, except for essential activities. The Governor continues to emphasize that we are still just at the beginning of this crisis in Maryland. While the State has been taking the lead with early containment efforts, we are now at a critical point. Each of our actions can lessen the expected surge in cases over the next few weeks.
Wednesday, March 25, 2020
As we continue to move forward in these challenging times, I would like to bring you a message of encouragement and hope. First and foremost, please be assured and confident that we are, and will continue to do, everything we can to ensure the health and well-being of all within our community. As you will see in this briefing, significant steps are being taken by the State of Maryland, the University of Maryland Medical System and the University of Maryland, Baltimore to ensure that everyone is healthy and safe. We must each do whatever is necessary to ensure that our health comes first.
Tuesday, February 25, 2020
Result is front-page feature coverage of UMSOM’s leading work in studying the Virus
Wednesday, January 29, 2020
University of Maryland School of Medicine Mobilizes Virus Experts to prepare for Potential Coronavirus Outbreak
As public health officials around the world are monitoring a new coronavirus strain (2019-nCoV) first identified in the Wuhan City, Hubei Province, China, the University of Maryland School of Medicine (UMSOM) is mobilizing its physicians and scientists in the UMSOM’s Center for Vaccine Development and Global Health (CVD), and in its Department of Microbiology & Immunology, to study the virus and test potential vaccines and other therapies. In addition, the UMSOM is collaborating with the University of Maryland Medical Center (UMMC) on rapid response and preparedness planning in the event of a growing outbreak.
Friday, April 14, 2000
The COVID-19 pandemic has changed many aspects of our lives, from the way we shop and eat to how we connect with family and friends. While the virus itself has had strong and sometimes devastating effects on our community, the fear of its potential impact continues to influence responses and even cripple thoughts and actions.